SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
December 2, 2005
Date of Report (Date of earliest event reported)
Haemonetics Corporation
(Exact Name of Registrant as Specified in its Charter)
Massachusetts
(State or Other Jurisdiction of Incorporation)
|
1-10730 |
|
04-2882273 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
400 Wood Road Braintree, MA |
|
02184 |
|
|
|
|
|
(Address of Principal Executive Office) |
|
(Zip Code) |
|
|
|
|
781-848-7100
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
|
|
|
Item 5.02 |
Election of New Director |
By a unanimous written consent dated December 2, 2005, the Company’s Board
of Directors elected Mark W. Kroll, Ph.D., to the Company’s Board of
Directors effective January 1, 2006. He will also serve on the Nominating
& Governance Committee of the Board.
Dr. Kroll’s compensation
will be in accordance with the standard compensation for non-employee Directors
of the Company as described in the Company’s previous SEC filings. In
accordance with such standard compensation, Dr. Kroll will receive on January 2,
2006, a grant of options for the purchase of 20,000 shares of the Company’s
common stock.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Haemonetics Corporation |
|
|
|
|
|
|
Date: December 6, 2005 |
By: |
/s/ Ronald J. Ryan |
|
|
|
|
|
|
|
Ronald J. Ryan, |
|
|
|
Vice President and Chief Financial Officer |
EXHIBIT INDEX
|
EXHIBIT 99.1 |
Press Release of Haemonetics Corporation dated December 6, 2005 announcing the election of Mark W. Kroll, Ph.D., as a Director. |
Exhibit 99.1
|
FOR RELEASE: |
CONTACT: |
|
Date: December 6, 2005 |
Julie Fallon |
|
Time: 10:30 AM EST |
Tel. (781) 356-9517 |
|
|
Alternate Tel. (617) 320-2401 |
|
|
fallon@haemonetics.com |
MARK KROLL JOINS HAEMONETICS’ BOARD OF DIRECTORS
BRAINTREE, MA, December 6, 2005 – Haemonetics Corporation announced that Mark W. Kroll, Ph.D., will join the Company’s Board of Directors effective January 1, 2006. He will also serve on the Nominating & Governance Committee of the Board. Dr. Kroll, aged 53, recently retired as Chief Technology Officer and Senior Vice President of the Cardiac Rhythm Management Division of St. Jude Medical, Inc., where he’d been employed since 1995.
Ronald A. Matricaria, Haemonetics’ Chairman of the Board, said, “Mark Kroll brings to Haemonetics a breadth of experience in technological innovation, including more than 20 years in research of technologies serving cardiovascular patients. As we focus on our strategy of business expansion, Mark’s expertise will complement the strengths and experiences already represented on our Board.”
Throughout his career, Dr. Kroll has been a leader in advanced technology. He holds 194 U.S. patents, many for inventions in implantable devices, and has been honored by the U.S. Patent and Trademark Office as a prolific inventor. He has lectured and published extensively on topics that include defibrillation, electrocardiology, cardiovascular devices, invention, and medical device start ups. He is a fellow of the American College of Cardiology.
Dr. Kroll is currently an Adjunct Professor of Biomedical Engineering, a Lecturer on cardiovascular physiology at the California Polytechnic State University, and a faculty member for the University of California Anderson School of Business annual program on creativity and innovation. Dr. Kroll holds a B.S. in mathematics, a Ph.D. in electrical engineering, and an M.B.A.
Dr. Kroll currently serves on the Board of Directors for Taser International, Inc.
Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at http://www.haemonetics.com.
###